Literature DB >> 32651849

Uric acid and risk of diabetic kidney disease.

Michael Mauer1, Alessandro Doria2.   

Abstract

Diabetic kidney disease (DKD) is the leading cause of end-stage kidney disease (ESKD) in the Western world. Better control of glycemia and blood pressure, including renin-angiotensin system blockade (RASB), appear to have slowed DKD progression rate but have been unable to substantially decrease the annual incidence of new cases of DKD related ESKD. Thus, new treatment targets are needed. Higher levels of serum uric acid (SUA) have been associated with increased risk and progression of DKD in persons with types 1 (T1D) and 2 (T2D) diabetes and of chronic kidney disease (CKD) in general. This review presents the epidemiological, clinical, and clinical trial evidence regarding the hypothesis that SUA reduction could slow progression of DKD and/or CKD in general.

Entities:  

Keywords:  Diabetes; Kidney disease; Uric acid

Year:  2020        PMID： 32651849     DOI： 10.1007/s40620-020-00796-z

Source DB:  PubMed          Journal:  J Nephrol        ISSN： 1121-8428            Impact factor:   3.902


  7 in total

1.  Noninvasive and Individual-Centered Monitoring of Uric Acid for Precaution of Hyperuricemia via Optical Supramolecular Sensing.

Authors:  Yaping Zhang; Huijuan Yu; Shiwei Chai; Xin Chai; Luyao Wang; Wen-Chao Geng; Juan-Juan Li; Yu-Xin Yue; Dong-Sheng Guo; Yuefei Wang
Journal:  Adv Sci (Weinh)       Date:  2022-04-28       Impact factor: 17.521

Review 2.  Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Renoprotective Mechanisms beyond Glycemic Control.

Authors:  Tomoaki Takata; Hajime Isomoto
Journal:  Int J Mol Sci       Date:  2021-04-22       Impact factor: 5.923

3.  Association between serum uric acid and renal outcome in patients with biopsy-confirmed diabetic nephropathy.

Authors:  Yutong Zou; Lijun Zhao; Junlin Zhang; Yiting Wang; Yucheng Wu; Honghong Ren; Tingli Wang; Rui Zhang; Jiali Wang; Yuancheng Zhao; Chunmei Qin; Huan Xu; Lin Li; Zhonglin Chai; Mark E Cooper; Nanwei Tong; Fang Liu
Journal:  Endocr Connect       Date:  2021-10-13       Impact factor: 3.335

4.  Effectiveness and safety of dapagliflozin in real-life patients: data from the DAPA-RWE Spanish multicentre study.

Authors:  Cristóbal Morales; Juan Francisco Merino-Torres; Paloma Moreno-Moreno; María Lainez; Iñigo Tejado; Alfredo Yoldi; Sonsoles Gutiérrez Medina; Alfonso Soto; Manuel A Botana; Virginia Bellido; Irene Caballero
Journal:  Drugs Context       Date:  2022-02-17

5.  Hyperuricemia Is Associated With the Risk of Atrial Fibrillation Independent of Sex: A Dose-Response Meta-Analysis.

Authors:  Jianhua Xiong; Wen Shao; Peng Yu; Jianyong Ma; Menglu Liu; Shan Huang; Xiao Liu; Kaibo Mei
Journal:  Front Cardiovasc Med       Date:  2022-04-07

6.  Prediction models for risk of diabetic kidney disease in Chinese patients with type 2 diabetes mellitus.

Authors:  Ling Sun; Yu Wu; Rui-Xue Hua; Lu-Xi Zou
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

Review 7.  Uric Acid and Oxidative Stress-Relationship with Cardiovascular, Metabolic, and Renal Impairment.

Authors:  Mihai-Emil Gherghina; Ileana Peride; Mirela Tiglis; Tiberiu Paul Neagu; Andrei Niculae; Ionel Alexandru Checherita
Journal:  Int J Mol Sci       Date:  2022-03-16       Impact factor: 5.923
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.